1 of 1
Story summary
- A study in eBioMedicine shows tirzepatide (the active ingredient in the diabetes drug Mounjaro) reduces alcohol consumption by more than 50% and prevents relapse-like behaviors in rodents.
- The drug blunts dopamine responses in the brain's reward system, particularly in the lateral septum.
- Tirzepatide is already FDA-approved for diabetes, suggesting potential for treating alcohol use disorder.
- However, human trials are needed to confirm safety and effectiveness for this use.
